Stockscreener 앱 받기
49.15
1.03%
0.50
시간 외 거래:
49.15
전일 마감가:
$48.65
열려 있는:
$48.74
하루 거래량:
5.43M
Relative Volume:
1.18
시가총액:
$99.14B
수익:
$42.06B
순이익/손실:
$7.96B
주가수익비율:
14.02
EPS:
3.5062
순현금흐름:
$5.64B
1주 성능:
+1.93%
1개월 성능:
+0.61%
6개월 성능:
+29.24%
1년 성능:
+44.35%
1일 변동 폭
$48.57
$49.16
1주일 범위
$47.62
$49.16
52주 변동 폭
$32.38
$51.46
글락소스미스클라인 ADR Stock (GSK) Company Profile
GSK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
49.15 | 98.13B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-04-15 | 개시 | Exane BNP Paribas | Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-11-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-07-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-03-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2024-01-03 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-03-17 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 재개 | Goldman | Buy |
| 2023-01-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-11 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-09-15 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 재개 | Citigroup | Neutral |
| 2022-02-11 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-06-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 개시 | Deutsche Bank | Hold |
| 2020-11-02 | 업그레이드 | Liberum | Hold → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-02-12 | 다운그레이드 | Shore Capital | Hold → Sell |
| 2020-01-16 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 개시 | SVB Leerink | Outperform |
| 2019-11-21 | 업그레이드 | UBS | Neutral → Buy |
| 2019-10-11 | 업그레이드 | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 재개 | Citigroup | Neutral |
| 2019-09-03 | 업그레이드 | Societe Generale | Sell → Buy |
| 2019-08-13 | 재개 | JP Morgan | Neutral |
| 2019-06-17 | 재개 | Morgan Stanley | Underweight |
| 2019-03-08 | 다운그레이드 | Shore Capital | Buy → Hold |
| 2019-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-14 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-08-30 | 다운그레이드 | Liberum | Buy → Hold |
| 2018-04-04 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | 업그레이드 | Kepler | Reduce → Hold |
모두보기
글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
GSK plc (ADR): Defensive Pharma Giant Tests Investors’ Patience As Shares Slip Despite Solid Pipel - AD HOC NEWS
Looking Into GSK PLC's Recent Short Interest - Sahm
Jefferies Reaffirms a Buy Rating on GSK plc (GSK)Here's Why - Finviz
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - TradingView — Track All Markets
GSK (NYSE:GSK) Lowered to “Underweight” Rating by Barclays - Defense World
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK - Sahm
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking - Sahm
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Sahm
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Finviz
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead - ts2.tech
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
글락소스미스클라인 ADR (GSK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.72%
자본화:
|
볼륨(24시간):